Elacytarabine, a novel 5'-elaidic acid derivative of cytarabine, and idarubicin combination is active in refractory acute myeloid leukemia

Francis Giles*, David Rizzieri, Farhad Ravandi, Ronan Swords, Tove Flem Jacobsen, Susan O'Brien

*Corresponding author for this work

Research output: Contribution to journalLetterpeer-review

15 Scopus citations

Fingerprint Dive into the research topics of 'Elacytarabine, a novel 5'-elaidic acid derivative of cytarabine, and idarubicin combination is active in refractory acute myeloid leukemia'. Together they form a unique fingerprint.